X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (793) 793
Publication (49) 49
Book Review (12) 12
Book Chapter (7) 7
Conference Proceeding (2) 2
Dissertation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cisplatin-based chemotherapy (695) 695
humans (595) 595
oncology (465) 465
index medicus (346) 346
chemotherapy (325) 325
male (305) 305
female (271) 271
cancer (256) 256
middle aged (224) 224
aged (215) 215
antineoplastic combined chemotherapy protocols - therapeutic use (209) 209
adult (187) 187
treatment outcome (140) 140
prognosis (130) 130
cisplatin - administration & dosage (128) 128
urology & nephrology (124) 124
bladder cancer (120) 120
neoplasm staging (100) 100
antineoplastic agents - therapeutic use (99) 99
phase-ii trial (96) 96
survival (95) 95
antineoplastic combined chemotherapy protocols - adverse effects (93) 93
care and treatment (93) 93
cisplatin (90) 90
urinary bladder neoplasms - drug therapy (85) 85
urothelial carcinoma (81) 81
retrospective studies (79) 79
testicular cancer (79) 79
risk factors (78) 78
transitional-cell carcinoma (77) 77
aged, 80 and over (76) 76
carcinoma (76) 76
urinary bladder neoplasms - pathology (76) 76
research (75) 75
antineoplastic agents - adverse effects (74) 74
combined modality therapy (73) 73
radical cystectomy (70) 70
gemcitabine (68) 68
pharmacology & pharmacy (67) 67
adjuvant chemotherapy (66) 66
carboplatin (65) 65
lung neoplasms - drug therapy (65) 65
cisplatin - therapeutic use (62) 62
radiotherapy (61) 61
survival analysis (61) 61
carcinoma, non-small-cell lung - drug therapy (60) 60
chemotherapy, adjuvant (59) 59
combination chemotherapy (58) 58
neoadjuvant chemotherapy (58) 58
urology (57) 57
metastasis (56) 56
phase-iii trial (56) 56
tumors (56) 56
analysis (55) 55
disease-free survival (55) 55
medicine & public health (53) 53
deoxycytidine - analogs & derivatives (52) 52
surgery (52) 52
survival rate (52) 52
quality-of-life (51) 51
testicular neoplasms - drug therapy (51) 51
drug therapy (50) 50
germ-cell tumors (50) 50
hematology, oncology and palliative medicine (50) 50
randomized-trial (50) 50
vinblastine (50) 50
carcinoma, transitional cell - drug therapy (49) 49
cooperative-oncology-group (49) 49
transitional-cell-carcinoma (49) 49
cisplatin - adverse effects (48) 48
adolescent (45) 45
antineoplastic agents - administration & dosage (45) 45
testicular neoplasms - therapy (45) 45
therapy (45) 45
toxicity (45) 45
antineoplastic combined chemotherapy protocols - administration & dosage (43) 43
deoxycytidine - administration & dosage (43) 43
high-dose chemotherapy (43) 43
cancer therapies (42) 42
double-blind (42) 42
health aspects (42) 42
carboplatin - administration & dosage (41) 41
cystectomy (41) 41
methotrexate (41) 41
neoplasms - drug therapy (41) 41
randomized controlled trials as topic (41) 41
neoadjuvant therapy (40) 40
ovarian neoplasms - drug therapy (40) 40
phase-iii (39) 39
hematology (38) 38
obstetrics & gynecology (38) 38
ovarian cancer (38) 38
follow-up studies (37) 37
gemcitabine plus cisplatin (37) 37
lymph-node dissection (37) 37
testicular neoplasms - pathology (36) 36
clinical trials as topic (35) 35
gynecologic-oncology-group (35) 35
neoplasm metastasis (35) 35
paclitaxel (35) 35
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (718) 718
German (27) 27
French (23) 23
Japanese (22) 22
Korean (2) 2
Spanish (2) 2
Chinese (1) 1
Hungarian (1) 1
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 05/2001, Volume 19, Issue 10, pp. 2647 - 2657
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 57, pp. 23 - 30
Abstract Objective Rolapitant, a novel neurokinin-1 receptor antagonist (RA), was shown to protect against delayed chemotherapy-induced nausea and vomiting... 
Hematology, Oncology and Palliative Medicine | Multiple cycles | Rolapitant | Neurokinin-1 receptor antagonist | Antiemetic | Chemotherapy-induced nausea and vomiting | Subsequent cycles | DEXAMETHASONE | PHASE-III | APREPITANT | ORAL NK1 ANTAGONIST | CANCER | RECEPTOR ANTAGONIST | CISPLATIN-BASED CHEMOTHERAPY | PHARMACOKINETICS | ONCOLOGY | DOUBLE-BLIND | ANTIEMETICS PROVIDES PROTECTION | Granisetron - administration & dosage | Nausea - chemically induced | Humans | Middle Aged | Antiemetics - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Spiro Compounds - administration & dosage | Male | Spiro Compounds - adverse effects | Serotonin 5-HT3 Receptor Antagonists - administration & dosage | Young Adult | Clinical Trials, Phase III as Topic | Aged, 80 and over | Adult | Antiemetics - adverse effects | Female | Drug Therapy, Combination | Vomiting - prevention & control | Granisetron - adverse effects | Dexamethasone - administration & dosage | Neurokinin-1 Receptor Antagonists - adverse effects | Double-Blind Method | Administration, Oral | Ondansetron - administration & dosage | Neurokinin-1 Receptor Antagonists - administration & dosage | Treatment Outcome | Neoplasms - drug therapy | Randomized Controlled Trials as Topic | Nausea - prevention & control | Retreatment | Vomiting - chemically induced | Aged | Ondansetron - adverse effects | Clinical Trials, Phase II as Topic | Prevention | Medical colleges | Chemotherapy | Nausea | Analysis | Cancer | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 10/2012, Volume 118, Issue 19, pp. 4785 - 4794
Journal Article
Journal of Urology, The, ISSN 0022-5347, 2014, Volume 191, Issue 1, pp. 40 - 47
Journal Article
Journal Article